EU Sickle Cell Disease Treatment Market, Market Segmented by Treatment type (Bone Marrow Transplant, Blood Transfusion, and Pharmacotherapy), by Drugs Brand (Endari, Adakveo, Oxbryta, Zynteglo, CTX001, Mitapivat, and FT-4202), and by End User (Hospitals, Specialty Clinics, and Others)- Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138171
- Pages: 200
-
Format:
Report Overview
The EU Sickle Cell Disease Treatment market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
SCD is a genetic condition that affects hemoglobin, a protein carried by the red blood cells that delivers oxygen throughout the body.3 It is caused by a genetic mutation and leads to the development of abnormally formed hemoglobin, which distorts red blood cells from a round to sickle (or crescent) shape.4 The sickling process causes the premature breakdown of red blood cells, leading to hemolytic anemia and inhibits red blood cells from passing through the small blood vessels, impeding the flow of oxygen
Market Drivers
The growing patient pool and high unmet medical needs are the key factors for the sickle cell disease treatment (SCD) market growth. Whereas increasing support from government and regulatory bodies by means of research and development and approval of discovering a newer treatment for SCD disorder are some growth factors expected to drive the SCD market during the forecast period
1. EU Sickle Cell Disease Treatment Market Overview
A. Market Size
2. EU Sickle Cell Disease Treatment Market Growth Drivers
A. The growing patient pool and high unmet medical needs
B. Increasing support from government and regulatory bodies by means of research and development
3. EU Sickle Cell Disease Treatment Market Segmentation
A. By Treatment Type
I. Bone Marrow Transplant
II. Blood Transfusion
III. Pharmacotherapy
B. By Drugs Brand
I. Endari
II. Adakveo
III. Oxbryta
IV. Zynteglo
V. CTX001
VI. Mitapivat
VII. FT-4202
C. By End User
I. Hospitals
II. Speciality Clinics
III. Others
4. EU Sickle Cell Disease Treatment Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Novartis, Company overview, Product & Services, Strategies & Financials
B. Add Medica, Company overview, Product & Services, Strategies & Financials
C. Bristol Myers Squibb, Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
